Corporate Magazine 2012 - Boehringer Ingelheim

Boehringer Ingelheim groupFINANCIAL HIGHLIGHTSAmounts in millions of EUR, unless otherwise indicated 2012 2011 ChangeNet sales 14,691 13,171 12%by regionEurope 29% 31%Americas 47% 46%Asia, Australasia, Africa 24% 23%by businessHuman Pharmaceuticals 93% 93%Animal Health 7% 7%Research and development 2,795 2,516 11%Personnel costs 4,024 3,664 10%Average number of employees 46,228 44,094 5%Operating income 1,853 2,272 — 18%Operating income as % of net sales 12.6% 17.3%Income after taxes 1,237 1,476 — 16%Income after taxes as % of net sales 8.4% 11.2%Shareholders‘ equity 6,178 7,466 — 17%Return on shareholders‘ equity 16.6% 22.8%Cash flow 2,225 2,378 — 6%Investments in tangible assets 562 458 23%Depreciation of tangible assets 793 535 48%Top 4 products — Prescription MedicinesNet sales 2012 in millions of EUR changespiriva® 3,562 + 13%micardis® 1,623 + 2%pradaxa® 1,108 + 76%combivent® 883 + 15%Top 4 products — Consumer Health CareNet sales 2012 in millions of EUR changebuscopan® 212 + 18%dulcolax® 193 + 13%mucosolvan® 166 + 4%pharmaton® 136 – 1%